Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acurx Pharmaceuticals, LLC*

0.3767
+0.00772.09%
Post-market: 0.37670.00000.00%16:00 EDT
Volume:53.50K
Turnover:20.21K
Market Cap:8.30M
PE:-0.43
High:0.3815
Open:0.3700
Low:0.3700
Close:0.3690
Loading ...

Acurx Announces Publication of Positive Results From an in-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of Cdi

THOMSON REUTERS
·
24 Feb

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

CNW Group
·
24 Feb

Acurx new patent granted by JPO related to DNA Polymerase IIIC Inhibitors

TIPRANKS
·
19 Feb

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

PR Newswire
·
19 Feb

Acurx Pharmaceuticals Says Selling Shareholders May Sell 2.6 Million Shares

MT Newswires Live
·
01 Feb

H.C. Wainwright Reaffirms Their Buy Rating on Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
13 Jan

Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Jan

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
08 Jan

BRIEF-Acurx Pharmaceuticals Announces $2.5 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Reuters
·
07 Jan

Acurx Launches $2.5 Million Registered Direct Offering; Shares Fall After-Hours

MT Newswires Live
·
07 Jan

Acurx to sell 2.46M shares at $1.015 in registered direct offering

TIPRANKS
·
07 Jan

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
07 Jan

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire
·
07 Jan

BRIEF-Acurx Receives Positive Regulatory Guidance From EMA For Ibezapolstat Phase 3 Program For CDI

Reuters
·
06 Jan

Acurx Receives Positive Regulatory Guidance From Ema for Ibezapolstat Phase 3 Program for C. Difficile Infection (Cdi)

THOMSON REUTERS
·
06 Jan

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

PR Newswire
·
06 Jan

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

ACCESSWIRE
·
12 Dec 2024

Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

BRIEF-FDA Provides Positive Feedback On Acurx's CMC Plan For Phase 3

Reuters
·
09 Dec 2024

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile Infection Based on Recent FDA and Ema Communications

THOMSON REUTERS
·
09 Dec 2024